NCT00475969已完成3 期
Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 327
- 试验地点
- 1
- 主要终点
- Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959)
研究概览
简要总结
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
详细描述
duloxetine 60 to 120 mg once daily (QD) and placebo 11 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female outpatients at least 18 years of age presenting with generalized anxiety disorder (GAD) based on the disease diagnostic criteria The patient must suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise specified (NOS). Symptoms of GAD should not be situational in nature.
- •Females of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who are not breastfeeding; test negative for pregnancy at the time of enrollment based on a urine pregnancy test; and agree to use a reliable method of birth control during the study and for 1 week following the last dose of study drug.
- •Must have a Clinical Global Impressions of Severity (CGI-Severity) score of greater than or equal to 4 at Visit 1 and Visit
- •At Visit 1, patient must have a Covi Anxiety Scale (CAS) score of greater than or equal to 9, no item in the Raskin Depression Scale (RDS) may be greater than 3, and the CAS must be greater than the RDS.
- •Must have a Hospital Anxiety and Depression Scale (HADS) anxiety subscale score of greater than or equal to 10 at Visit 1.
排除标准
- •Any current and primary DSM-IV Axis I diagnosis other than GAD.
- •Patients diagnosed with or who have a history of major depressive disorder (MDD) within the past 6 months or
- •Patients diagnosed with or who have a history of Panic Disorder, Post-Traumatic Stress Disorder (PTSD), or an eating disorder within the past year or
- •Patients who have been diagnosed with Obsessive Compulsive Disorder (OCD), Bipolar Affective Disorder, psychosis, factitious disorder, or somatoform disorders during their lifetime.
- •The presence of an Axis II disorder or history of antisocial behavior, which, in the judgment of the investigator, would interfere with compliance with the study protocol.
- •Benzodiazepine use 14 days prior to Visit
- •Patients judged clinically to be at serious suicidal risk, or patients who, in the opinion of the investigator, are poor medical or psychiatric risks for study completion.
- •Have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
结局指标
主要结局
Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959)
次要结局
- Sheehan Disability Scale (SDS) Global Functional Impairment score (Sheehan 1983)
- Hospital Anxiety Depression Scale (HADS; Zigmond and Snaith 1983)
- Clinical Global Impressions of Improvement scale (CGI-Improvement; Guy 1976)
- Patient's Global Impressions of Improvement scale (PGI-Improvement; Guy 1976)
- Symptom Questionnaire-Somatic Subscale (SQ-SS)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Duloxetine 60 mg Once Daily Versus Placebo in the Treatment of Patients with Osteoarthritis Knee PainDuloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo en el Tratamiento de Pacientes con Dolor Artrósico de RodillaDolor Artrosico de Rodilla Osteoarthritis Knee PainMedDRA version: 9Level: LLTClassification code 10031166Term: Osteoarthritis kneesEUCTR2009-010008-27-ESilly S.A.422
进行中（未招募）
不适用
Duloxetine 60 mg once daily versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain - HMGPOsteoarthritis Knee PainMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-010008-27-SEEli Lilly and Company422
进行中（未招募）
不适用
Duloxetine 60 mg once daily versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain - HMGPEUCTR2009-010008-27-DEEli Lilly and Company422
进行中（未招募）
1 期
Duloxetine 60 mg once daily versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain - HMGPOsteoarthritis Knee PainMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2009-010008-27-GREli Lilly and Company422
已完成
4 期
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly PatientsMajor Depressive DisorderNCT00406848Eli Lilly and Company370